To this effect, standard operational procedures are constantly being developed by the EMEA Secretariat for consideration and adoption by the CPMP, for example on “ Annual re-assessment of the specific obligations and the benefit/ risk profile of medicinal products authorised under exceptional circumstances” (CPMP/ SOP/ 657/ 97).